ReviewExperimental diabetes research2012
Cell-based therapies for diabetic complications.
Review in Experimental diabetes research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances.Current diabetes reviews · 2025Review
- Novel lipid mediator 7Frontiers in cell and developmental biology · 2024Article
- Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.International journal of molecular sciences · 2022Review
- E3 ligase activity of Carboxyl terminus of Hsc70 interacting protein (CHIP) in Wharton's jelly derived mesenchymal stem cells improves their persistence under hyperglycemic stress and promotes the prophylactic effects against diabetic cardiac damages.Bioengineering & translational medicine · 2021Article
- Setd4 controlled quiescent c-KitScientific reports · 2021Article
- Concise review: current trends on applications of stem cells in diabetic nephropathy.Cell death & disease · 2020Review
- Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications.Journal of diabetes research · 2018Review
- Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy.Stem cell reviews and reports · 2017Review
- Compromised Neurotrophic and Angiogenic Regenerative Capability during Tendon Healing in a Rat Model of Type-II Diabetes.PloS one · 2017Article
- Basic Fibroblast Growth Factor Inhibits Apoptosis and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients with Type 2 Diabetes by Reducing Cellular Oxidative Stress.Oxidative medicine and cellular longevity · 2017Article
- Glucose and acute exercise influence factors secreted by circulating angiogenic cells in vitro.Physiological reports · 2016Article
- Bone marrow derived stem cell therapy for type 2 diabetes mellitus.Stem cell investigation · 2016Article
- Viability, differentiation capacity, and detectability of super-paramagnetic iron oxide-labeled muscle precursor cells for magnetic-resonance imaging.Tissue engineering. Part C, Methods · 2015Article
- The Role of Bone Marrow Cells in the Phenotypic Changes Associated with Diabetic Nephropathy.PloS one · 2015Article
- Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus.Frontiers in endocrinology · 2014Review
- Combination therapy accelerates diabetic wound closure.PloS one · 2014Article
- Article
- Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise.Cardiovascular diabetology · 2012Review
- It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications.Experimental diabetes research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly benefit from cell-based therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular complications affecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic benefits that these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.